139 related articles for article (PubMed ID: 12641328)
21. Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients.
Vogt M; Kunath K; Dressman JB
Eur J Pharm Biopharm; 2008 Feb; 68(2):330-7. PubMed ID: 17574401
[TBL] [Abstract][Full Text] [Related]
22. Effect of physical properties of troglitazone crystal on the molecular interaction with PVP during heating.
Hasegawa S; Furuyama N; Yada S; Hamaura T; Kusai A; Yonemochi E; Terada K
Int J Pharm; 2007 May; 336(1):82-9. PubMed ID: 17178201
[TBL] [Abstract][Full Text] [Related]
23. Mebendazole crystal forms in tablet formulations. An ATR-FTIR/chemometrics approach to polymorph assignment.
Calvo NL; Kaufman TS; Maggio RM
J Pharm Biomed Anal; 2016 Apr; 122():157-65. PubMed ID: 26874854
[TBL] [Abstract][Full Text] [Related]
24. PCA-CR analysis of dissolution profiles. A chemometric approach to probe the polymorphic form of the active pharmaceutical ingredient in a drug product.
Maggio RM; Castellano PM; Kaufman TS
Int J Pharm; 2009 Aug; 378(1-2):187-93. PubMed ID: 19477254
[TBL] [Abstract][Full Text] [Related]
25. Development of a discriminating in vitro dissolution method for a poorly soluble NO-donating selective cyclooxygenase-2 inhibitor.
Papp R; Luk P; Mullett WM; Kwong E; Debnath S; Thibert R
J Pharm Biomed Anal; 2008 May; 47(1):16-22. PubMed ID: 18272312
[TBL] [Abstract][Full Text] [Related]
26. Analysis of mebendazole polymorphs by Fourier transform IR spectrometry using chemometric methods.
Aboul-Enein HY; Bunaciu AA; Fleschin S
Biopolymers; 2002; 67(1):56-60. PubMed ID: 11842414
[TBL] [Abstract][Full Text] [Related]
27. Nanosized bicalutamide and its molecular structure in solvents.
Le Y; Ji H; Chen JF; Shen Z; Yun J; Pu M
Int J Pharm; 2009 Mar; 370(1-2):175-80. PubMed ID: 19101616
[TBL] [Abstract][Full Text] [Related]
28. Preparation of ultrafine fenofibrate powder by solidification process from emulsion.
Huang QP; Wang JX; Zhang ZB; Shen ZG; Chen JF; Yun J
Int J Pharm; 2009 Feb; 368(1-2):160-4. PubMed ID: 19010406
[TBL] [Abstract][Full Text] [Related]
29. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
30. Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior.
Kimura K; Hirayama F; Uekama K
J Pharm Sci; 1999 Apr; 88(4):385-91. PubMed ID: 10187747
[TBL] [Abstract][Full Text] [Related]
31. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
Kim MS; Jin SJ; Kim JS; Park HJ; Song HS; Neubert RH; Hwang SJ
Eur J Pharm Biopharm; 2008 Jun; 69(2):454-65. PubMed ID: 18359211
[TBL] [Abstract][Full Text] [Related]
32. Solid state evaluation of some thalidomide raw materials.
Carini JP; Pavei C; Silva AP; Machado G; Mexias AS; Pereira VP; Fialho SL; Mayorga P
Int J Pharm; 2009 May; 372(1-2):17-23. PubMed ID: 19162152
[TBL] [Abstract][Full Text] [Related]
33. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance.
Agrawal S; Ashokraj Y; Bharatam PV; Pillai O; Panchagnula R
Eur J Pharm Sci; 2004 Jun; 22(2-3):127-44. PubMed ID: 15158898
[TBL] [Abstract][Full Text] [Related]
34. Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method.
Qiu Y; Garren J; Samara E; Cao G; Abraham C; Cheskin HS; Engh KR
J Pharm Sci; 2003 Nov; 92(11):2317-25. PubMed ID: 14603516
[TBL] [Abstract][Full Text] [Related]
35. Mebendazole mesylate monohydrate: a new route to improve the solubility of mebendazole polymorphs.
de Paula K; Camà GE; Brusau EV; Narda GE; Ellena J
J Pharm Sci; 2013 Oct; 102(10):3528-38. PubMed ID: 23897162
[TBL] [Abstract][Full Text] [Related]
36. Micronization of gemfibrozil by reactive precipitation process.
Huang QP; Wang JX; Chen GZ; Shen ZG; Chen JF; Yun J
Int J Pharm; 2008 Aug; 360(1-2):58-64. PubMed ID: 18502064
[TBL] [Abstract][Full Text] [Related]
37. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
Jantratid E; De Maio V; Ronda E; Mattavelli V; Vertzoni M; Dressman JB
Eur J Pharm Sci; 2009 Jun; 37(3-4):434-41. PubMed ID: 19491035
[TBL] [Abstract][Full Text] [Related]
38. Solubility and intrinsic dissolution rate of alprazolam crystal modifications.
Laihanen N; Muttonen E; Laaksonen M
Pharm Dev Technol; 1996 Dec; 1(4):373-80. PubMed ID: 9552321
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and characterization of a new mebendazole salt: mebendazole hydrochloride.
Brusau EV; Camà GE; Narda GE; Cuffini S; Ayala AP; Ellena J
J Pharm Sci; 2008 Jan; 97(1):542-52. PubMed ID: 17854049
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the impact of sodium lauryl sulfate source variability on solid oral dosage form development.
Qiang D; Gunn JA; Schultz L; Li ZJ
Drug Dev Ind Pharm; 2010 Dec; 36(12):1486-96. PubMed ID: 20545515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
